Sign Up Now!
To sign up for our newsletter or print publications, please enter your contact information below.
First Name *
Last Name *
Email Address (Verify) *
We will request your mailing address on the next page.
We will request your mailing address on the next page.

Role of Exercise and Energy Conservation in the Management of Fatigue in Patients with NSCLC Receiving Immune-Oncology Therapy

2021 Year in Review - Non–Small-Cell Lung Cancer - Lung Cancer

Cancer-related fatigue occurs on most days over the course of the disease, lasts at least 2 weeks, and interferes with daily activities.1 Throughout the course of the disease, fatigue is the most frequently reported symptom in patients with lung cancer.1

Antineoplastic therapies are known to cause treatment-related tiredness, complicating an already difficult situation. Fatigue is the most common adverse event in patients on immune checkpoint inhibitors, which are the new standard of care in non–small-cell lung cancer (NSCLC) treatment.1

Exercise and physical activity, according to a significant body of data, improves the general health of patients with cancer and may help them live longer.2 Physical activity has been linked to a lower incidence of a variety of cancers in humans, and some evidence suggests that it may have a clinical benefit for patients with cancer.3 Exercise causes immune system cells to mobilize and redistribute to different bodily compartments, and exercise has been demonstrated to cause immunologic alterations in the tumor microenvironment in preclinical models. This suggests that combining exercise and immunotherapy may have a synergistic impact.3 The advantages of exercise include physical well-being, calm, freedom, relaxation, and improved sleep quality.

Given the substantial link between exercise and better outcomes in patients with cancer, strengthening systemic immunity and patient immunologic responses through exercise could be a complementary method to boosting immunotherapy responses, allowing for a more effective therapeutic response.2 Numerous studies have recently been published that provide some intriguing information about how exercise affects immune cell populations and function. The scientific premise that physical activity and exercise can help the immune system recover and optimize its responses to cancer is well-documented.2

The fatigue caused by cancer and further fatigue caused by immune checkpoint inhibitor treatment is an unfortunate aspect of cancer, including NSCLC. To maintain a patient’s functionality, nurses should become proactive advocates for physical activity throughout and after therapy. A well-thought-out progressive program of restorative exercise and energy-saving skills can help manage fatigue as a therapeutic complement to antineoplastic treatment. Aerobic exercise for at least 30 minutes a day for 5 days per week is an ideal exercise routine for patients with cancer to strive toward, if they can manage.3

References

  1. Almeida C, Chemela R. The role of physical exercise and energy conservation in the management of fatigue in NSCLC patients under IO. Ann Oncol. 2021;32(suppl 5):S1278.
  2. Gustafson MP, Wheatley-Guy CM, Rosenthal AC, et al. Exercise and the immune system: taking steps to improve responses to cancer immunotherapy. J ImmunoTherapy Cancer. 2021;9:e001872.
  3. Olofsson GH, Jensen AWP, Idorn M, Straten PT. Exercise oncology and immune-oncology; a (future) dynamic duo. Int J Mol Sci. 2020;21:3816.
Related Items
NSCLC Year in Review Introduction
2021 Year in Review - Non–Small-Cell Lung Cancer published on December 29, 2021 in Lung Cancer
The Impact of Symptom Severity on Multidisciplinary Tumor Board Treatment Decisions
2021 Year in Review - Non–Small-Cell Lung Cancer published on December 29, 2021 in Lung Cancer
Targeted Therapy and Immunotherapy May Improve NSCLC Survival Rates
2021 Year in Review - Non–Small-Cell Lung Cancer published on December 29, 2021 in Lung Cancer
CodeBreaK 100 Phase 2 Study Results Demonstrate Sotorasib Efficacy
2021 Year in Review - Non–Small-Cell Lung Cancer published on December 29, 2021 in Lung Cancer
FDA Grants Accelerated Approval of Sotorasib for Patients with NSCLC Harboring KRAS Mutations
2021 Year in Review - Non–Small-Cell Lung Cancer published on December 29, 2021 in Lung Cancer
Impact of Hyperglycemia in Patients with Advanced NSCLC with PD-L1 ≥50% Treated with Frontline Pembrolizumab
2021 Year in Review - Non–Small-Cell Lung Cancer published on December 29, 2021 in Lung Cancer
A Retrospective Study Shows Different Lung Imaging Patterns Among Different Cancer Types
2021 Year in Review - Non–Small-Cell Lung Cancer published on December 29, 2021 in Lung Cancer
Sotorasib Demonstrates Clinical Benefit in Patients with NSCLC and KRASᴳ¹²ᶜ
2021 Year in Review - Non–Small-Cell Lung Cancer published on December 29, 2021 in Lung Cancer
Anxiety and Depression Among Oncology-Treated Patients with Cancer
2021 Year in Review - Non–Small-Cell Lung Cancer published on December 29, 2021 in Lung Cancer
Breaking the Barriers to NGS Testing in Oncology Care: Physician-Reported Strategies
2021 Year in Review - Non–Small-Cell Lung Cancer published on December 29, 2021 in Lung Cancer
Copyright © Green Hill Healthcare Communications, LLC. All rights reserved.